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Laboratory, Department of Health Studies, University of Chicago, Chicago, IL 60637; and §Department of Genetics, Dartmouth Medical School,
Lebanon, NH 03755
Communicated by Xiaodong Wang, University of Texas Southwestern Medical Center, Dallas, TX, May 10, 2007 (received for review April 21, 2007)
The early phases of carcinogenesis resemble embryonic develop-
ment, often involving the reexpression of embryonicmesenchymal
genes. The NCI60 panel of human tumor cell lines can genetically
be subdivided into two superclusters (SCs) that correspond to CD95
Type I and II cells. SC1 cells are characterized by amesenchymal and
SC2 cells by an epithelial gene signature, suggesting that SC1 cells
represent less differentiated, advanced stages of cancer. miRNAs
are small 20- to 22-nucleotide-long noncoding RNAs that inhibit
gene expression at the posttranscriptional level. By performing
miRNA expression analysis on 10 Type I and 10 Type II cells, we
have determined that SC1 cells express low and SC2 cells high
levels of the miRNA let-7, respectively, suggesting that let-7 is a
marker for less advanced cancers. Expression of the let-7 target
high-mobility group A2 (HMGA2), an early embryonic gene, but
not of classical epithelial or mesenchymal markers such as E-
cadherin or vimentin, inversely correlated with let-7 expression in
SC1 and SC2 cells. Using ovarian cancer as amodel,we demonstrate
that expression of let-7 and HMGA2 is a better predictor of
prognosis than classical markers such as E-cadherin, vimentin, and
Snail. These data identify loss of let-7 expression as a marker for
less differentiated cancer.
HMGA2  miRNA  ovarian cancer  tumor progression  supercluster
It has been demonstrated that miRNAs act either as oncogenes(e.g., miR-155, miR-17–5p, and miR-21) (1, 2) or tumor suppres-
sors (e.g., miR-15a, miR-16–1, and let-7) (3–7). Members of the
ubiquitously expressed let-7/miR-98 family are expressed late in
mammalian embryonic development (4–9), and in humans let-7 has
been shown to act as a tumor suppressor for lung and colon cancer,
in part through targeting of RAS (4–7). It is becoming increasingly
evident that miRNAs play an important role in oncogenesis by
regulating genes that are involved in transformation. Because there
are 25,000 to 30,000 genes in the human genome, but only 400
miRNAs, there may be miRNA families that govern entire gene
expression programs presumably by regulating a distinct pattern of
differentiation. We previously identified two cell types that can be
classified by the way they respond to stimulation of the death
receptor, CD95 (Fas/APO-1) (12). We subsequently demonstrated
that CD95-sensitive Type I (mitochondria-independent death) and
Type II (mitochondria-dependent death) cells correspond to su-
percluster (SC)1 and SC2 cells, respectively [supporting informa-
tion (SI) Fig. 7] (13, 14). To determine whether miRNAs could be
responsible for the differences seen between SC1 and SC2 cells, we
performed an miRNA gene array analysis. We report the identi-
fication of the let-7 family of miRNAs as being preferentially
expressed in SC2 cells and identify high-mobility group A2
(HMGA2) as a direct let-7 target that is preferentially expressed in
SC1 cells. Testing ovarian cancer (OC) as a model, we demonstrate
that let-7 andHMGA2 serve as prognostic markers for this disease.
We identify low let-7 and high HMGA2 expression as markers for
advanced cancer.
Results and Discussion
Let-7 Genes Are Preferentially Expressed in Type II/SC2 Cells. To
determine whether miRNA could regulate the difference between
Type I and II cells, we subjected 10 Type I/SC1 and 10 Type II/SC2
cell lines to anmiRNAexpression array analysis (Fig. 1A). Detected
miRNAs were sorted based on their expression in the two groups.
Fourmembers of the let-7 family ofmiRNAs (let-7f, let-7d,miR-98,
and let-7g) were preferentially expressed in SC2 cells (P  0.001).
This result was confirmed by using quantitative real-time RT-PCR;
all four let-7 miRNAs were expressed significantly higher in Type
II cells than in Type I cells (Fig. 1B). By performing a nonpara-
metricWilcoxon two sample rank test, we determined that seven of
the nine let-7 family members on the chip were significantly higher
expressed in Type II cells, with let-7d and let-7g being the best
differentiators (SI Fig. 8). These seven let-7 family members also
clustered together in a hierarchical cluster analysis (SI Fig. 9).
To determine whether the results with a subset of NCI60 cells
also applied to all of the NCI60 cells, we interrogated a data set of
miRNA expression that was recently generated with 59 of the
NCI60 cells (15). Let-7d showed the highest significance of pref-
erential expression in the Type II and SC2 cells, correlating well
with our own analysis (Fig. 1C and data not shown). This analysis
confirms that Type I cells represent SC1 cells and Type II cells
represent SC2 cells. Although there was overlap between the
groups, let-7d expression discriminates between the two SCs more
effectively than any of the previously tested mRNAs (13).
Identification of HMGA2 as a Direct Target for Let-7 in Human Cancer
Cell Lines. To identify genes that are up-regulated in SC1 cells, we
searched for putative let-7 targets employing four of the most
widely used programs to predict miRNA targets (TargetScan,
TargetScanS, PicTar, and miRNAviewer) (16). All four algorithms
predictedHMGA2as the number one target (SI Fig. 10), consistent
with recent reports identifying HMGA2 as a let-7 target (10, 11).
The 3-UTR of human HMGA2 contains seven putative let-7
complementary sites (LCSs) (Fig. 2A). To test whether introduc-
tion of let-7 could reduce expression ofHMGA2 in a human cancer
cell line that expresses low let-7, we transfected HepG2 cells that
have high HMGA2 expression with three different let-7 precursor
miRNAs: let-7a, let-7c, and let-7g. HMGA2 expression was sub-
stantially reduced on introduction of the let-7 miRNAs (Fig. 2B).
Introduction of exogenous let-7a, let-7c, or let-7g caused degrada-
tion of HMGA2 mRNA (Fig. 2C). To determine whether expres-
sion of HMGA2 in cancer cells may be suppressed by endogenous
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levels of let-7 found in SC2 cells, we transfected the high let-7-
expressing HeLa cells with inhibitors of let-7 (Fig. 2D). Both a
mixture of inhibitors specific for let-7a, let-7c, and let-7g and the
let-7g inhibitor alone caused induction of HMGA2 protein expres-
sion, indicating that it is let-7 expression that prevents HMGA2
expression in these cells.
It was recently demonstrated that five of the seven LCSs in the
3UTR of human HMGA2 are functional (10). The two distal
LCSs, 6 and 7, are identical in the 3UTRof humans andmice, with
LCS6 showing the highest degree of identity with let-7 family
members (SI Fig. 11). To determine whether targeting these two
LCSs was sufficient to suppress expression of HMGA2, we cloned
a fragment of the 3UTR containing LCS6/7 into a luciferase
reporter plasmid and determined how transfection of let-7 affects
luciferase activity (Fig. 2E). Both let-7d and let-7g caused signifi-
cant repression of luciferase activity of full-length 3UTR as well as
the 6/7 fragment (Fig. 2E and data not shown). Mutation of either
one of the two seed matches in the 6/7 fragment caused a moderate
reduction of the ability of let-7 to suppress luciferase activity.When
both LCS in the 6/7 fragment were mutated, let-7g could not
suppress luciferase activity anymore when compared to the effect
on control plasmid (Fig. 2E). These data suggest that both distal
LCSs in the HMGA2 3UTR are targets for let-7, in contrast to a
recent report (10), and they are sufficient to regulate HMGA2
expression.
It has recently been shown that tumor cells express lower levels
of miRNAs than primary tissues (17), raising the question of
whether the differences in let-7 expression between SC1 and SC2
tumor cell lines are functionally significant and whether the level of
let-7 detected in these cells could control expression of HMGA2.
We therefore quantified the amount of HMGA2 protein in the
NCI60 cells and compared its expression with the let-7 expression
in every cell line. Because SC1 cells express a mesenchymal gene
signature and SC2 cells an epithelial gene signature, we also
Fig. 1. Identification of let-7 as a marker for Type II/SC2 cells. (A) Gene array analysis of the expression of miRNAs in 10 Type I and 10 Type II cell lines. Seventy-nine
of 287 human miRNAs on the chip were significantly expressed in the 20 cell lines (see Methods and SI Table 1). No single miRNA was found to be equally expressed
in all cells, suggesting that miRNAs do not have general housekeeping functions in tumor cells. The expression of miRNAs between SC1 and SC2 cells was therefore
calculatedrelativetothemeanofthesignal intensitiesof the79miRNAsthatareexpressed inthe20tumorcells (SITable2). ShownareallmiRNAsthatweresignificantly
expressed (see Methods) and sorted according to P values from t tests of expression differences between Type I or II cell lines. Four miRNAs with a highly significant
P value of0.001 are boxed with a stippled line. (B) Relative fold difference of let-7d, mir-98, let-7a/f, and let-7g expression between the 10 Type I and 10 Type II cancer
cell lines measured by real-time PCR. Data were normalized by determining the ratio of let-7 expression to that of the small nuclear RNA U6 as described before (33).
The let-7/U6 ratios were plotted relative to the ratio found in HepG2 cells. HeLa and HepG2 cells were chosen as positive or negative controls for let-7 expression,
respectively. We determined that the probe for let-7f does not discriminate between let-7f and let-7a (data not shown). (C) Analysis of the expression of let-7d in 59
of the NCI60 cells. (Left) Expression of let-7d in the 22 Type I (blue) and Type II (red) cells previously identified among the NCI60 cells (13) is shown. (Left) Expression in
the SC1 (blue) and SC2 (red) cell lines among the 59 NCI60 cells is shown. The asterisk marks an outlier in the SC1 group. Without this one value, the P value changed
to 0.0012 (two sample t test). In this independent performed analysis, we compared the expression of let-7d relative to the mean of expression of a very similar set of
65 miRNAs that was used to analyze the miRNA chip data (SI Table 2).
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determined protein expression ofE-cadherin (an epithelialmarker)
and vimentin (a mesenchymal marker) in the two cell types (Fig. 3
and SI Fig. 12). This analysis revealed a significant inverse corre-
lation between the expression of let-7d, let-7g, and let-7f and
HMGA2 in individual cell lines (Fig. 3 and SI Fig. 13). We did not
find such a correlation between the expression of let-7 and E-
cadherin or vimentin (Fig. 3 and SI Fig. 13). The inverse ratio of
expression of let-7 and HMGA2 characterizes the difference be-
tween SC1 and SC2 cells and could therefore be an indicator for
more or less advanced human cancer.
Let-7 Regulates HMGA2 Expression in OC and Predicts Disease Pro-
gression. Now that we established that endogenous let-7 levels
found in SC2 cells can control HMGA2 expression, we sought to
test the significance of these findings for human cancer progression.
Therefore, we examined the expression of let-7 at different stages
of OC. OC develops from a single layer of cells on the surface of
the ovary and progresses to an aggressive, dedifferentiated cancer
expressing mesenchymal markers (18, 19). Recently, it was shown
that genomic alterations affecting the expression of let-7 are found
in OC (20). In view of our findings, we tested whether the
correlation between let-7 and HMGA2 held for six randomly
selected epithelial OC lines (Fig. 4A andB). Three of the tested cell
lines expressed low amounts of let-7, whereas three expressed high
levels (Fig. 4A). Only the three cell lines expressing low let-7
expressed HMGA2 (Fig. 4B), and introduction of let-7d or let-7g
into these cell lines abrogated HMGA2 expression, demonstrating
that let-7 can target HMGA2 in OC cells (Fig. 4C and data not
shown).
Next we determined the expression level of HMGA2 in tissues
from patients with OC (Fig. 5A). HMGA2 was undetectable in
normal ovarian surface epithelium or benign ovarian tumors, but
expressed in patients with OC (Fig. 5A). Although normal appear-
ing ovarian epithelium did not express HMGA2 (Fig. 5B Inset),
tumor cells in the early stage represented by in situ cancers (see
Inset) clearly expressed theHMGA2protein, and its expression was
further increased in full-blown carcinoma (C in Fig. 5B). These data
suggest that HMGA2 expression is up-regulated early on transfor-
mation of ovarian epithelial cells.
Given our results that loss of let-7 induces HMGA2 expression
and identifies a mesenchymal cancer subtype (similar to SC1 cells),
we sought to determine whether expression of HMGA2 is associ-
ated with patient prognosis. A human tissue microarray containing
samples from primary tumors of 100 patients with International
Federation of Gynecology and Obstetrics (FIGO) stages II-IV
advanced OC was stained for HMGA2 protein expression. High
expression of HMGA2 correlated significantly with an adverse
prognosis both for progression-free (Fig. 6A) and overall survival
(SI Fig. 14) of the patients. No significant difference was found in
the expression of HMGA2 between primary tumors and corre-
sponding omental or peritoneal metastases from the same patients
(P  0.5909). These data indicate that HMGA2 expression is a
marker for early tumor progression and not for metastasis.
HMGA2was shown to be up-regulated in advanced cancers, and
its expression correlates with poor prognosis (21–25). Because let-7
regulates the expression of HMGA2, we investigated whether let-7
is down-regulated in OC tissue from patients with an adverse
prognosis. RNA was extracted from tumor tissues with low (100)
staining and compared to tumor tissues with high (160) staining
for HMGA2 from patients analyzed in Fig. 6A. A significantly
higher expression of let-7d was detected in the patient group with
low HMGA2 intensity (Fig. 6B). In contrast, no significant corre-
lation between the expression of E-cadherin or vimentin and
progression-free or overall survival was found (SI Fig. 14). We also
did not find a correlation between the expression of Snail and either
progression-free survival or let-7d expression (SI Fig. 15). Finally,
a combined score of let-7d and HMGA2 expression was also able
to separate the patients into two groups (Fig. 6C): The estimate of
5-year progression-free survival in the groupwith a lowerHMGA2/
let-7 ratio was 39.7% (95% confidence interval: 21.4–57.6%). The
estimate of 5-year progression-free survival in the group with a
higher HMGA2/let-7 ratio was 9.6% (95% confidence interval:
1.8–25.4%).
Our data suggest that human tumors can be divided into two
major subtypes, the let-7hi- and let-7lo-expressing tumor cells. The
separation of tumor cells into two such SCs may not be restricted
to the NCI60 cells. A similar separation into two major clusters was
observed in unsupervised hierarchical cluster analyses of cDNAs in
cell lines or primary tumor samples from patients with breast (26),
ovarian (27), and other cancers (28). In all these cases, in addition
to tumor- and class-specific gene clusters, two SCs emerged from
the analyses. The differences in gene expression between the SCs
Fig. 2. Identification of HMGA2 as a direct target of let-7. (A) Schematic of
the 3UTR at the human HMGA2 genomic locus located on chromosome 12.
The gray box depicts the 3-end of the ORF, whereas the horizontal line depicts
the 3-UTR spanning3 kb. Solid rectangles indicate the precise locations with
nucleotide positions on chromosome 12 of the seven putative let-7 binding
sites and the seed match to the let-7 family of miRNAs. The dotted line located
at the distal end of the 3-UTR represents the fragment of the 3-UTR con-
taining the sixth and seventh putative let-7 sites that was used for the Renilla
reporter experiments in Fig. 2E. (B) HMGA2 protein expression is negatively
regulated by let-7. HepG2 cells were transiently transfected with let-7a, let-7c,
let-7g, or control precursor miRNA. -actin was detected to demonstrate
equal loading. Ctrl, scrambled control. (C) HMGA2 RNA is degraded with
increased levels of let-7. HepG2 cells were transfected with miRNAs as in Fig.
2B, and after 72 h mRNA for HMGA2 was detected by RT-PCR. -actin is shown
as a control. (D) Induction of HMGA2 protein through inhibiting let-7. HeLa
cells were transfected either with a mixture of let-7a, let-7c, and let-7g (total
of 180 pmol) or with let-7d (60 pmol) inhibitor alone. Scr, scrambled oligonu-
cleotide as controls at two concentrations; Scr.1, 180 pmol; Scr.2, 60 pmol. (E)
HMGA2 is posttranscriptionally regulated through the 3-UTR by let-7. Renilla
luciferase reporter assays were performed with reporter plasmid psiCHECK
(ctr), psiCHECK-HMGA2 full-length 3-UTR (FL), or psiCHECK-HMGA2 3-UTR
6/7 (6/7), together with either 1 pmol of premiR scrambled (S) or premiR let-7g
(7g). PsiCHECK-HMGA2 3-UTR 6/7mt6 (6/7mt6), psiCHECK-HMGA2 3-UTR
6/7mt7 (6/7mt7), or psiCHECK-HMGA2 3-UTR 6/7mt6,7 (6/7mt6,7), which
harbor mutations in the seed matches in either LCS6, LCS7, or both, were also
used in the luciferase assay experiment. Renilla luciferase activity was nor-
malized to the internally controlled firefly luciferase activity.
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were larger than any differences between tumor types in these
analyses. Recently, the analysis of miRNA expression among dif-
ferent normal tissues also resulted in the separation of tissues into
two similar sized SCs (29). Interestingly, the miRNA that best
allowed the separation of these two SCs was let-7a, suggesting that
the concept of two SCs separated by their expression levels of let-7
may not be limited to tumor cells.
The two tumor types that are characterized by the expression of
let-7 go beyond the conventional definition of epithelial and
mesenchymal cells. The gene expression profiles corresponding to
SC1 and SC2 cells, as described by Ross et al. (14), do not always
yield morphological features. Many of the established ‘‘epithelial’’
cell lines among the NCI60 cells, such as PC3, Hs578T, BT-549,
U251, A549, H226, ACHN, CAKI-1, OVCAR-5, IGROV-I,
EKVX, and H460, separated into SC1 in the hierarchical cluster
analysis (SI Fig. 7). In addition,many lymphoid cell lines that cannot
be viewed as being derived fromepithelial tissues clustered together
with the epithelial group. However, because the gene signature of
SC2 cells overall has an epithelial character, classical definitions of
epithelial cells may not be applicable anymore. It appears that
whole gene expression patterns can be regulated by miRNAs, and
let-7 is a good candidate to define this ‘‘epithelial’’ gene signature.
Consequently, let-7 was found to be superior in differentiating SC2
from SC1 cells to established markers such as E-cadherin or
vimentin.
One of the models used to explain carcinogenesis suggests that,
during cancer progression, a number of embryonic genes that are
not expressed in adult tissues are reexpressed, causing tumors to
dedifferentiate and become more mobile and invasive in a manner
similar to embryonic cells (30). Because tumor cells with a mes-
enchymal gene profile represent more advanced stages of cancer,
let-7 down-regulation could be seen as part of the process of tumor
progression. Recently, it was demonstrated that impaired miRNA
processing accelerates oncogenic transformation (31). Altering
let-7 expression levels caused a change in tumorigenicity in a
number of cancer cell lines (31). These data were taken to support
the finding that a global reduction of miRNAs increases oncogenic
potential of cancer cells. Our work now focuses on the loss of
members of the let-7 family as the major determinant of cancer
progression because no other miRNA was allowed to differentiate
SC1 from SC2 cells as effectively (see SI Table 1). We propose that
one of the functions of let-7 is to maintain differentiated states by
suppressing the expression of genes that are expressed in dediffer-
entiated tissues, such as HMGA2.
Fig. 3. Analysis of the protein expression levels of HMGA2, E-cadherin, and vimentin, and correlation with let-7d expression in 59 NCI60 cell lines. Protein
expression was determined by Western blotting (see SI Fig. 12). Expression levels in SC1 cells are shown as blue dots and SC2 cells as red dots. Predicted let-7d
values from a univariate linear regression are plotted against protein expression. Pearson correlation coefficients (r) and P values (p) are reported.
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Fig. 4. HMGA2 in OC cell lines is under control of let-7. (A) Relative fold
difference of let-7d, let-7g, and let-7a/f miRNA expression in six randomly
chosen OC cell lines measured by real-time PCR and normalized to U6 expres-
sion. A, A2780; C, CAOV3; H, HeyA8; I, IGROV-I; O, OVCAR-5; S, SKOV3ip. Two
sample t test results are shown. (B) Western blot analysis of the same cells
analyzed in A. Let-7hi/HMGA2lo cells in A and B are labeled in red, let-7lo/
HMGA2hi cells in blue. -actin was detected to demonstrate equal loading. (C)
The three HMGA2-expressing cells were transfected with let-7g, and HMGA2
protein amount was determined by Western blotting. -actin was detected to
demonstrate equal loading. S, scrambled control.
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Fig. 5. HMGA2 expression is increased early in OC progression. (A) Immu-
nohistochemistry for HMGA2 of representative normal (Left Upper) and tu-
mor tissues (Right Upper and Lower) from OC patients. (Magnification: tu-
mors, 200; ovary, 400.) Arrowhead points to the surface epithelium of a
normal ovary in a patient with a benign tumor. (B) Immunohistochemical
detection of HMGA2 in tumor from a patient with advanced OC. C, carcinoma;
O, ovary.
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Methods
miRNA Chip Analysis. miRNA was enriched from cells by using the
mirVana miRNA Isolation Kit (Ambion, Austin, TX). Size distri-
bution of enriched miRNAs was confirmed by using the Agilent
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Probes
were labeled by attaching a 20- to 50-nucleotide tail of a mixture of
ATP and amine-modified ATP to the 3 end of miRNA using
Escherichia coli poly(A) polymerase. The amine-modified miRNA
was then coupled to Cy5 dye. The Cy5-labeledmiRNAwas cleaned
and hybridized at 42°C for 16 h to the mirVana miRNA bioarray.
After a wash and drying step, the array was scanned at a PMT
setting of 600 with 100% power and 5-m resolution with the
GenePix pro 4.1 software in theGenePix 4000Bmicroarray scanner
(Axon Instruments, Union City, CA). To determine relative ex-
pression levels of miRNA in different tumor cells, four miRNAs
(miR103, miR107, miR93, and miR191) were selected on the chip
that had roughly similar expression levels in all cell lines. The
expression of all miRNAs was normalized to themean of these four
invariant miRNAs. The sum of the signal intensity of all 20 cell lines
was calculated. There were 87 human miRNAs with cumulative
signal intensity1,000 that were used for further analysis (with the
highest signal of 326,169 for miR21). Fold change was calculated,
and a two sample t test was conducted to test for differences in the
expression between the two cell types. miRNAs were sorted by P
value. This preliminary analysis identified four let-7 family mem-
bers as being preferentially expressed in Type II cells with a
significant P value. To refine this analysis, we recalculated the
signals by normalizing all values to the mean of all significantly
expressed human miRNAs (not including let-7 family members)
(see SI Table 2). All signals were divided by the mean of these
miRNAs. Negative values were set to zero. When all samples were
added again for each row (miRNA), the highest value was 143.31
(for miR-21) and the lowest was 0.58 (for miR-132). The eight
miRNAs below a value of 1.0 were deleted. Significance analysis of
the remaining 79 significantly expressed miRNAwas performed by
using a two-tailed t test with unequal variance. Samples were sorted
according to P value, and a hierarchical cluster analysis was
performed by using Dchip and default settings. Additionally, a
Wilcoxon rank test was conducted to test whether there was a
difference in let-7 expression for each of the nine let-7 miRNAs
between the two cell types (SI Fig. 8).
Real-Time PCR. microRNA was enriched from cells by using the
mirVana miRNA Isolation Kit (Ambion). microRNA and U6-
specific cDNA was generated from between 10 and 20 ng of
enriched or FFPETRNA by using the TaqManMicroRNARTKit
and the RNA-specific RT primer from the TaqMan microRNA
Assays (Applied Biosystems, Foster City, CA). miRNA levels were
also measured by using the miRNA-specific TaqMan MGB probe
included with the MicroRNA Assays on a 7,500 quantitative
real-time PCR machine and SDS software (Applied Biosystems).
miRNA abundance was normalized relative to U6. For the analysis
of let-7 in 59 NCI60 cells, data sets containing the expression levels
of let-7d, let-7g, let-7f, miR-98, and miR-63 control miRNAs
obtained by real-time PCR using total RNA (15) were provided by
Mark Israel (Dartmouth Medical School, Lebanon, NH). The
expression level of let-7d relative to themean of 63 controlmiRNAs
(see SI Table 2) was determined for each cell line. Snail gene
expression was quantified in ovarian tumor tissues by using cDNA
generated from 100 ng RNA extracted from formalin-fixed paraf-
fin-embedded tissue (FFPET) by using the High-Capacity cDNA
RTKit (AppliedBiosystems) andTaqManGeneExpressionAssays
for Snai1 (Mm00441533g1; Applied Biosystems) and human
-glucoronidase (4333767T; Applied Biosystems) as an endoge-
nous control. Relative levels of miRNA or mRNA gene expression
were calculated by using the 2CT method.
RNA Extraction from FFPET. RNA was extracted from FFPET using
the MasterPureRNA Purification Kit (Epicenter Technologies,
Madison,WI) according to themanufacturer’s instructions with the
following modifications: Punched-out plugs (1.5  1.5 mm) of a
paraffin block were deparaffinized in 1 ml of ACS grade Xylene
(Fisher, Pittsburgh, PA) and incubated at 65°C for 10 min, followed
by a 100% ACS grade ethanol (Sigma–Aldrich, St. Louis, MO)
wash. Samples were then incubated with proteinase K at 65°C
overnight while shaking. After the isopropanol precipitation step,
samples were incubated with DNase I for 30 min at 37°C to ensure
the removal of all contaminating genomic DNA. RNA samples
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Fig. 6. HMGA2 and let-7d expression inversely correlate with survival of OC patients. (A) Progression-free survival of 100 OC patients depending on the staining
intensity for HMGA2. Primary tumors from 100 patients (with FIGO stage II–IV) on a tissue array were stained for HMGA2. Splitting the group at the median
resulted in 0 132 and 1 132. Only samples with5% HMGA2-positive cells were included. The patient group is described in SI Table 3. (B) Expression of let-7d
in RNA samples extracted from tumor tissue with low100 (n 8) or high160 (n 9) HMGA2 staining. Fold difference relative to the sample with the lowest
let-7d expression (set to 1) is shown. Expression of let-7d was normalized to U6. P value is the result of two sample t test. (C) Progression-free survival by the ratio
of HMGA2 intensity to let-7 CT (splitting at the median: 0 54 and 1 54 high) including 53 subjects with FIGO stage II, III, or IV and HMGA 2% positive5%.
Note that two let-7 CT values 0 were given a threshold value of 0.20.
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were resuspended in nuclease-free water after the final precipita-
tion steps, and quality and quantity were assessed by using the
ND-1000 spectrophotometer (Nanodrop, Wilmington, DE). The
paraffin plugs were enriched for tumor tissue bymicroscope control
by using H&E-stained sections of the same sample as guidance.
Constructs and Mutagenesis. The human HMGA2 3-UTR (Gen-
Bank accession no. X92518, bases 1645–4218) was PCR-amplified
from pBAC clone RP11–1025D9 with primers 5-AAAACTC-
GAGGCCAACGTTCGATTTCTACCT-3 and 5- AAAAGCG-
GCCGCTACTGTTCCATTGGCCACAA-3 that contain NotI
andXhoI restriction site overhangs, respectively. This PCRproduct,
which contains seven putative let-7 binding sites, was cloned into the
psiCHECK-2 vector (Promega, Madison, WI) immediately down-
stream of the Renilla luciferase reporter gene and named psi-
CHECK-HMGA2 3-UTR. ADNA stretch containing LCS6 and 7
(4023–4218) was PCR-amplified with primers 5-AAAACTC-
GAGGGATGGGCCTTTTAGAAACC-3 and 5-AAAAGCG-
GCCGCTACTGTTCCATTGGCCACAA-3 that contain NotI
and XhoI restriction site overhangs, respectively, and cloned into
psiCHECK generating psiCHECK-HMGA2 3-UTR 6/7. Site-
directed mutagenesis was performed by using the QuikChange II
XL site-directed mutagenesis kit (Stratagene, La Jolla, CA) to
change three nucleotides in the second, fourth, and sixth positions
in the seed matches of LCS6 and 7. The seed sequence of LCS6
CTACCTCwas substituted by CAAGCAC, and LCS7 was changed
from TACCTCA to TTCGTGA. The mutations were generated in
the psiCHECK-HMGA2 3-UTR 6/7 construct and named psi-
CHECK-HMGA2 3-UTR 6/7mt6 and pSICHECK-HMGA2
3UTR 6/7mt7 for a single-seed match mutation and psiCHECK-
HMGA2 3-UTR 6/7mt6/7 for double-seed match mutations.
Transfection and Luciferase Assay. The 293TN cells (2.5 104) were
seeded in eachwell of a 48-well plate 1 day before transfection. Cells
were transfected with either psiCHECK, psiCHECK-HMGA2 3-
UTR, psiCHECK-HMGA2 3-UTR 6/7, or psiCHECK-HMGA2
3-UTR 6/7 mutants together with either PremiR let-7g or negative
control #1 precursor miRNA (Ambion) using Lipofectamine 2000
(Invitrogen, Carlsbad, CA). After 48 h, cells were lysed and
measured for luciferase activity according to the manufacturer’s
instructions (Promega). All experiments were performed in tripli-
cates and normalized to the activity of the Renilla luciferase gene
that is contained within the psiCHECK-2 vector as an internal
control.
Analysis of OC Tumor Microarray. Tissue blocks from 107 patients
withFIGOstages II–IVadvancedOCor peritoneal cancerwhohad
undergone tumor debulking by a Gynecologic Oncologist at the
Section of Gynecologic Oncology, University of Chicago, between
1994 and 2004were selected for the study after Institutional Review
Board approval was obtained. A tumor microarray was assembled,
and clinicopathological parameters collected as described (32).
Satisfactory immunohistochemical staining of HMGA2 was ob-
tained in 100 patients (see SI Table 3 for details).
Additional Details. Additional methods are described in SI Text.
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